Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000 Read More
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board Read More
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board Read More
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments Read More
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials Read More
